(Q79257785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Community-acquired pneumonia in the elderly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Vladimir Kaplan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Derek C Angus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

published in

Critical Care Clinics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

729-748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Prospective study of the aetiology and outcome of pneumonia in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The outcome of community acquired pneumonia treated on the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia requiring hospitalization: 5-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Patients hospitalized after initial outpatient treatment for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Causes of pneumonia presenting to a district general hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Hospital study of adult community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Severe community-acquired pneumonia. Etiology, prognosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Aetiology and outcome of severe community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Impact of management guidelines on the outcome of severe community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

International comparisons of critical care outcome and resource consumption

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Nursing home-acquired pneumonia. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The cost of treating community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Pneumonia: still the old man's friend?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia: impact of immune status

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia requiring hospitalization. Is it different in the elderly?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Prospective hospital study of community acquired lower respiratory tract infection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

A hospital study of community acquired pneumonia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia in the elderly. Clinical and nutritional aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Raised respiratory rate in elderly patients: a valuable physical sign

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Early management of younger adults dying of community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Predicting death in patients hospitalized for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community acquired pneumonia: aetiology and usefulness of severity criteria on admission

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Severe community-acquired pneumonia. Assessment of severity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Diagnosing pneumonia by physical examination: relevant or relic?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Influence of blood culture results on antibiotic choice in the treatment of bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Parapneumonic effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Management of complicated parapneumonic effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The use of noninvasive positive pressure ventilation in the emergency department: results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Aetiology and outcome of severe community-acquired pneumonia in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Clinical effectiveness of influenza vaccination in Manitoba

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2803%2900057-5

7 January 2021

10.1016/S0749-0704(03)00057-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14601717%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference